Press Release

Home / Press Release

BERLIN, Germany, April 14, 2020 – AMP German Cannabis Group Inc. (“AMP” or the “Company”) (CSE: XCX) (FSE: C4T, ISIN: CA00176G1028) is pleased to announce it has successfully obtained all the required licences to import, store at its licensed narcotic storage facility and distribute to its pharmaceutical distributors irradiated EU-GMP certified medical cannabis flower. The Federal Institute for Drugs and Medical Devices (BfArM) granted an irradiation permit to AMP Alternative Medical Products GmbH (“AMP Germany”), a wholly-owned subsidiary...

BERLIN, Germany, April 3rd, 2020 – AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028) is pleased to announce that it has successfully increased the loan amount it can borrow on its drawn down loan facility announced on December 3rd, 2018 from €500,000 to €1,000000 to finance trade receivables from the import of medical cannabis from the Netherlands in the coming weeks.  The amended drawdown facility will mature December 31, 2021, and borrowed amounts can be repaid...

BERLIN, Germany, March  9, 2020 – AMP German Cannabis Group Inc. (“AMP” or the “Company”) (CSE: XCX) (FSE: C4T, ISIN: CA00176G1028) announces that the Thuringian State Office for Consumer Protection or Thüringer Landesamt für Verbraucherschutz, (“TLV”) has granted an additional import licence for cannabis products for medical purposes from European countries to Germany in accordance to Paragraph §52a of the German Medicine Law or Arzneimittelgesetz to Alternative Medical Products GmbH (“AMP Germany”), a wholly-owned subsidiary of AMP.     TLV deals with fundamental matters of economic...

BERLIN, Germany, March 6th, 2020 – AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028) announces it has closed the first tranche of its non-brokered private placement previously announced on January 8th, 2020. Under the first tranche, AMP raised gross proceeds of $867,500 through the issuance of 3,470,000 common shares at a subscription price of $0.25 per share.  AMP paid a finders’ fee of $10,500 and issued 42,000 finders’ warrants. Each finders’ warrant entitles the holder to...

BERLIN, Germany, January 15th, 2020 – AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028) provides an update on its strategy to become one of the leading importers of European Union - Good Manufacturing Practices (EU-GMP) medical cannabis into Germany through its network of suppliers from Canada, Europe and other non-European countries.   2019 Highlights Share floatation on the Canadian Securities and Frankfurt Stock Exchanges, Secured C$750,000 (€500,000) revolving drawdown loan facility, Raised C$1.5-million (€1,035,000) in Series A...

BERLIN, Germany, January 8, 2020 – AMP German Cannabis Group Inc. (“AMP” or the “Company”) (CSE: XCX) (FSE: C4T, ISIN: CA00176G1028) announces a non-brokered placement of up to 8,000,000 common shares of the Company at a price of $0.25 per share for gross proceeds of up to $2,000,000. The Company intends to use the net proceeds from the offering to fund its import business, general corporate purposes and working capital. All securities issued pursuant to the offering will be subject to a...

Berlin and Erfurt, Germany - November 18, 2019 –– AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028) announces the Thuringian State Office for Consumer Protection (Thueringer Landesamt fuer Verbraucherschutz) (“TLV”) has granted an import licence for cannabis products for medical purposes for Germany according to Section 72 of the German Medicine Law (Arzneimittelgesetz - AMG) to Alternative Medical Products GmbH (“AMP Germany”), a wholly-owned subsidiary of AMP.   The TLV deals with fundamental matters of economic consumer protection and...

AMP to supply the growing Germany market with pharmaceutical medical cannabis imported from Canada ERFURT and BERLIN, Germany, October 15, 2019 – AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028) through its wholly-owned subsidiary AMP Alternative Medical Products GmbH (“AMP Germany”) has entered into a four-year, non-exclusive, distribution agreement with CC Pharma GmbH (“CC Pharma”), a leading distributer of EU-pharmaceuticals products to more than 13,000 pharmacies throughout Germany.  The agreement provides for monthly shipments of imported European Union...

BERLIN, Germany, October 10, 2019 –– AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028) announces that it has begun conducting an European Union (EU) Good Manufacturing Procedure (EU-GMP) audit of its supply chain logistics in Germany to ensure that the quality and integrity of pharmaceutical goods during transportation and storage is maintained throughout the supply chain from the supplier to the German patient.     EU-GMP certification is an internationally recognized system that ensures all pharmaceutical goods, including medical cannabis,...

BERLIN, Germany, October 8, 2019 –– AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028) announces that it has entered into a non-binding memorandum of understanding to purchase up to 1,200 kilograms of either branded or white-labeled European Union - Good Manufacturing Practice (EU-GMP) medical cannabis flower annually from an Alberta based supplier with a cultivation and processing licence from Health Canada (“Alberta LP”).        AMP and the Alberta LP will begin imports upon the Alberta LP receiving a sales...